Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Licenses Clinomics Cancer Database

NEW YORK, March 30 (GenomeWeb News) - Clinomics has licensed its Oncology Cell Signalling Database to AstraZeneca, the company's parent, Cytomyx holdings, said today.


The searchable database includes over 30,000 tissue samples from different forms of human cancer, and protein expression of 100 cell signaling proteins across all of these samples, the company said. It allows companies to biologically characterize gene and protein targets in numerous diseases, through searching numerous data fields including medical history, pathology, demographics, and treatment outcomes.


Under the non-exclusive agreement, AstrZeneca has obtained multiple user licenses to the database.


Cytomyx, of Cambridge, UK, acquired Clinomics in December 2003.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.